keyword
MENU ▼
Read by QxMD icon Read
search

DCR

keyword
https://www.readbyqxmd.com/read/27913881/phase-ii-trial-of-s-1-plus-leucovorin-in-patients-with-advanced-gastric-cancer-and-clinical-prediction-by-s-1-pharmacogenetic-pathway
#1
Ming-Ming He, Dong-Sheng Zhang, Feng Wang, Zi-Xian Wang, Shu-Qiang Yuan, Zhi-Qiang Wang, Hui-Yan Luo, Chao Ren, Miao-Zhen Qiu, Ying Jin, De-Shen Wang, Dong-Liang Chen, Zhao-Lei Zeng, Yu-Hong Li, Yang-Yang He, Yuan-Tao Hao, Pi Guo, Feng-Hua Wang, Yi-Xin Zeng, Rui-Hua Xu
BACKGROUND: The first one-arm phase II trial aimed to evaluate and predict efficacy and safety of S-1 plus oral leucovorin (S-1/LV) as first-line chemotherapy for patients with advanced gastric cancer (AGC), using S-1 pharmacogenetic pathway approach. PATIENTS AND METHODS: A total of 39 patients orally took S-1 at conventional dose and LV simultaneously at a dose of 25 mg twice daily for a week, within a 2-week cycle. The primary endpoint was overall response rate (ORR), while the secondary endpoints were progression-free survival (PFS), time to failure (TTF), overall survival (OS), disease control rate (DCR), and adverse events (AEs)...
December 2, 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27911869/paclitaxel-oxaliplatin-fluorouracil-tof-regimen-versus-s-1-oxaliplatin-sox-regimen-for-metastatic-gastric-cancer-patients
#2
Xichao Dai, Xizhi Zhang, Chaomin Wang, Jingting Jiang, Changping Wu
AIMS AND BACKGROUND: This study was designed to compare the efficacy and safety of paclitaxel/oxaliplatin/fluorouracil (TOF) regimen and S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer (GC) patients. METHODS: Sixty patients were divided into TOF group and SOX groups randomly. Patients in the TOF group received paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5. The patients in the SOX group received oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg~60mg orally twice/day based on body surface area) on days 1-14...
November 30, 2016: Oncotarget
https://www.readbyqxmd.com/read/27901493/has-aidi-injection-the-attenuation-and-synergistic-efficacy-to-gemcitabine-and-cisplatin-in-non-small-cell-lung-cancer-a-meta-analysis-of-36-randomized-controlled-trials
#3
Zheng Xiao, Chengqiong Wang, Ling Chen, Xuemei Tang, Lianhong Li, Nana Li, Jing Li, Qihai Gong, Fushan Tang, Jihong Feng, Xiaofei Li
Gemcitabine and cisplatin is the first line chemotherapy for non-small cell lung cancer with high toxicity. Aidi injection is a cantharidin and astragalu-based Chinese herbs injection in China. Has Aidi injection attenuation and synergistic efficacy to GP in NSCLC? There is lack of strong evidence to prove it. To further reveal it, we systematically evaluated all related studies. We collected all studies about Aidi injection plus GP for NSCLC in Medline, Embase, Web of Science, CNKI, VIP, Wanfang Database, CBM, CCRCT, Chi-CTR, and US-clinical trials (established to June 2015)...
November 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27894494/optimal-fluid-therapy-for-traumatic-hemorrhagic-shock
#4
REVIEW
Ronald Chang, John B Holcomb
The resuscitation of traumatic hemorrhagic shock has undergone a paradigm shift in the last 20 years with the advent of damage control resuscitation (DCR). Major principles of DCR include minimization of crystalloid, permissive hypotension, transfusion of a balanced ratio of blood products, and goal-directed correction of coagulopathy. In particular, plasma has replaced crystalloid as the primary means for volume expansion for traumatic hemorrhagic shock. Predicting which patient will require DCR by prompt and accurate activation of a massive transfusion protocol, however, remains a challenge...
January 2017: Critical Care Clinics
https://www.readbyqxmd.com/read/27893423/efficacy-and-safety-of-icotinib-in-treating-non-small-cell-lung-cancer-a-systematic-evaluation-and-meta-analysis-based-on-15-studies
#5
Rong Biaoxue, Liu Hua, Gao Wenlong, Yang Shuanying
Icotinib is a new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that developed and used in China; this work was to evaluate its efficacy and safety in treating non-small cell lung cancer (NSCLC). Clinical studies evaluating the efficacy and safety of icotinib in treating NSCLC were identified from the databases of Medline, Web of Science, Embase and Cochrance Library. Pooled efficacy and safety of icotinib were calculated through a series of predefined search strategies. A total of 15 studies with 2,304 patients were involved in this study...
November 22, 2016: Oncotarget
https://www.readbyqxmd.com/read/27881011/adjuvant-chemotherapy-with-bevacizumab-i-p-can-prolong-survival-time-of-patients-with-advanced-ovarian-cancer-after-cytoreduction
#6
F DU, P Li, J Chen, Z Gong, C Chi, B Hu, H Chu
Objective To assess whether adjuvant chemotherapy with bevacizumab intraperitoneal (i.p.) is better than adjuvant chemotherapy with bevacizumab intravenous (i.v.) or adjuvant chemotherapy only for patients with advanced ovarian cancer after cytoreduction. Selected patients with advanced ovarian cancer after cytoreduction were divided into three groups depend on their will: adjuvant chemotherapy only; adjuvant chemotherapy combined with bevacizumab intravenous (i.v.); adjuvant chemotherapy combined with bevacizumab intraperitoneal (i...
November 24, 2016: Neoplasma
https://www.readbyqxmd.com/read/27866515/-outcomes-and-toxicity-of-concurrent-radiotherapy-with-carboplatin-paclitaxel-%C3%A2-administrated-every-three-weeks-in-inoperable-advanced-%C3%A2-non-small-cell-lung-cancer-%C3%A2-a-retrospective-study-from-a-single-center
#7
Jing Zhao, Xiaotong Zhang, Ke Hu, Hanping Wang, Yan Xu, Xiaoyan Si, Wei Zhong, Xia Huang, Li Zhang, Mengzhao Wang
BACKGROUND: Standard care for patients with inoperable advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy. The ideal concurrent chemotherapy regimen has not been determined. The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide. METHODS: The 43 patients with inoperable advanced NSCLC receiving concurrent chemotherapy in Peking Union Medical College Hospital from January 2012 to June 2014 were enrolled and analyzed...
November 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/27863436/chemotherapy-plus-dendritic-cells-co-cultured-with-cytokine-induced-killer-cells-versus-chemotherapy-alone-to-treat-advanced-non-small-cell-lung-cancer-a-meta-analysis
#8
Cuiling Zhou, Donglan Liu, Jie Li, Huanhuan Sun, Xiaobin Zheng, Shuncong Wang, Guobin Hong, Saradhi Mallampati, Hongliu Sun, Xiuling Zhou, Zhibin Cheng, Hongyu Zhang, Haiqing Ma
This study was aimed to investigate the efficacy and safety of the combination treatment of dendritic cells co-cultured with cytokine-induced killer cells and chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC). Literatures were searched from the Cochrane Library Central, PubMed, Web of Science and EMBASE. The primary endpoint of interest was overall survival (OS), and secondary endpoints were disease control rate (DCR) and progression free survival (PFS). Finally 7 trials published between January 2005 and March 2016 met inclusion criteria and totally 610 patients were enrolled...
November 16, 2016: Oncotarget
https://www.readbyqxmd.com/read/27858864/can-aidi-injection-restore-cellular-immunity-and-improve-clinical-efficacy-in-non-small-cell-lung-cancer-patients-treated-with-platinum-based-chemotherapy-a-meta-analysis-of-17-randomized-controlled-trials-following-the-prisma-guidelines
#9
Zheng Xiao, Chengqiong Wang, Yongping Sun, Nana Li, Jing Li, Ling Chen, Xingsheng Yao, Jie Ding, Hu Ma
BACKGROUND: Aidi injection is an adjuvant chemotherapy drug commonly used in China. Can Aidi injection restore the cellular immunity and improve the clinical efficacy in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy? There is a lack of strong evidence to prove it. To further reveal it, we systematically evaluated all related studies. We collected all studies about the clinical efficacy and cellular immunity of Aidi injection plus platinum-based chemotherapy for NSCLC in Medline, Embase, Web of Science, China national knowledge infrastructure database (CNKI), Chinese Scientific Journals Full-Text Database (VIP), Wanfang, China biological medicine database (CBM) (established to June 2015), Cochrane Central Register of Controlled Trials (CCRCT) (June 2015), Chinese clinical trial registry, and US-clinical trials (June 2015)...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27853012/outcomes-of-endoscopic-dacryocystorhinostomy-experience-of-a-fellowship-trainee-at-a-tertiary-care-center
#10
Saurabh Kamal, Mohammad Javed Ali, Akshay Gopinathan Nair
AIM: The study aims to report a single trainee's experience of learning and performing endoscopic endonasal dacryocystorhinostomy (En-DCR). SETTINGS AND DESIGN: This study was a retrospective, interventional case series. SUBJECTS AND METHODS: Fifty-four eyes of fifty patients presenting at a tertiary eye care center over 1 year were included in the study. All cases underwent endoscopic DCR with mitomycin-C and silicone intubation. The parameters studied included demographics, clinical features, intraoperative details, and postoperative ostium evaluation...
September 2016: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/27852922/abnormal-expression-of-trail-receptors-in-decidual-tissue-of-chlamydia-trachomatis-infected-rats-during-early-pregnancy-loss
#11
Jinzhi Lu, Liya Zhu, Lei Zhang, Jinpeng Jiang, Fang Xie, Qing Huang, Xiaolan Li, Cunjian Yi
Chlamydia trachomatis is the scientific name of pathogenic bacteria causing infection that has been linked to spontaneous abortion. In this study, the expression pattern of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL; a cytokine related to cell apoptosis) and its receptors was monitored in the decidua of C trachomatis-infected pregnant rats during early gestation to investigate the potential role of this molecular system in C trachomatis-induced spontaneous abortion. The data showed that C trachomatis infection significantly altered the messenger RNA (mRNA) expression of the receptors; death receptor (DR) 4 and DR5 increased, but decoy receptor (DcR) 1 and DcR2 decreased...
November 16, 2016: Reproductive Sciences
https://www.readbyqxmd.com/read/27842586/hyaline-cartilage-calcification-of-the-first-metatarsophalangeal-joint-is-associated-with-osteoarthritis-but-independent-of-age-and-bmi
#12
Jan Hubert, Thelonius Hawellek, Sandra Hischke, Jessica Bertrand, Matthias Krause, Klaus Püschel, Wolfgang Rüther, Andreas Niemeier
BACKGROUND: Hyaline cartilage calcification (CC) is associated with osteoarthritis (OA) in hip and knee joints. The first metatarsophalangeal joint (1(st)MTPJ) is frequently affected by OA, but it is unclear if CC occurs in the 1(st)MTPJ. The aim of the present study was to analyze the prevalence of CC of the 1(st)MTPJ in the general population by high-resolution digital contact radiography (DCR) and to determine its association with histological OA severity, age and body mass index (BMI)...
November 15, 2016: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/27842514/thoracic-perfusion-of-recombinant-human-endostatin-endostar-combined-with-chemotherapeutic-agents-versus-chemotherapeutic-agents-alone-for-treating-malignant-pleural-effusions-a-systematic-evaluation-and-meta-analysis
#13
Rong Biaoxue, Cai Xiguang, Liu Hua, Gao Wenlong, Yang Shuanying
BACKGROUND: Endostar is a new endogenous angiogenic inhibitor with implicated anti-tumor activity. This study was to investigate whether thoracic perfusion of Endostar could be used to control malignant pleural effusions (MPE). METHODS: We searched the databases of MEDLINE, Web of Science, EMBASE, Goggle, Cochrance Library and CNKI to select the studies regarding the efficacy of Endostar to treat MPE. A total of 13 randomised controlled trials (RCTs) with 1066 patients were included...
November 14, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27835912/a-network-meta-analysis-of-eight-chemotherapy-regimens-for-treatment-of-advanced-ovarian-cancer
#14
Xi-Ping Jiang, Xiao-Hui Rui, Cai-Xia Guo, Ya-Qing Huang, Qin Li, Yun Xu
This study compared the short-term efficacies of different chemotherapy regimens in the treatment of advanced ovarian cancer (AOC) through pair-wise and network meta-analyses (NMA). Randomized controlled trials (RCTs) identified in a comprehensive online literature search met our inclusion criteria. Direct and indirect evidence was combined to compare odds ratios (OR) and surfaces under the cumulative ranking curves (SUCRA) across the different treatment regimens. Twelve eligible RCTs were finally included, involving eight regimens (Paclitaxel + Carboplatin [PC], Gemcitabine + Carboplatin [GC], Carboplatin, Pegylated Liposomal Doxorubicin + Carboplatin [PLD + Carboplatin], Paclitaxel, Paclitaxel + Carboplatin + Topotecan [PC + Topotecan], Paclitaxel + Carboplatin + Epirubicin [PC + Epirubicin] and Docetaxel + Carboplatin [DC])...
November 9, 2016: Oncotarget
https://www.readbyqxmd.com/read/27821319/a-phase-ii-study-of-sorafenib-in-recurrent-and-or-metastatic-salivary-gland-carcinomas-translational-analyses-and-clinical-impact
#15
L D Locati, F Perrone, B Cortelazzi, C Bergamini, P Bossi, E Civelli, C Morosi, S Lo Vullo, M Imbimbo, P Quattrone, G P Dagrada, R Granata, C Resteghini, A Mirabile, S Alfieri, E Orlandi, L Mariani, G Saibene, S Pilotti, L Licitra
BACKGROUND: Pre-clinical and clinical evidence suggests a rationale for the use of anti-angiogenic agents, including sorafenib, in recurrent and/or metastatic salivary gland carcinomas (RMSGCs). This study evaluates the activity of sorafenib in patients with RMSGCs and also investigates whether the activity of sorafenib could be related to its main tailored targets (i.e. BRAF, vascular endothelial growth factor receptor 2 [VEGFR2], platelet-derived growth factor receptor α [PDGFRα] and β, RET, KIT)...
November 4, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27817053/magnetic-resonance-imaging-in-the-pre-operative-evaluation-of-obstructive-epiphora-true-fisp-and-vibe-vs-gadolinium
#16
Francesco Somma, Vincenzo d'Agostino, Fabio Tortora, Nicola Serra, Gerardo Sorrentino, Valeria Piscitelli, Andrea Somma, Mario Gamerra
PURPOSE: To assess unenhanced magnetic resonance imaging (MRI) in the preoperative evaluation of obstructive epiphora in patients undergoing dacryocystorhinostomy (DCR) and in particular, to evaluate the efficacy of this technique in the detection of the exact level of obstruction occurring in the naso-lachrymal duct (NLD). The correct identification and characterization of the NLD and its obstructions lead to a more effective surgery, preventing recurrent dacryocystitis after the surgical treatment...
November 5, 2016: La Radiologia Medica
https://www.readbyqxmd.com/read/27806321/a-network-meta-analysis-on-the-efficacy-of-sixteen-targeted-drugs-in-combination-with-chemotherapy-for-treatment-of-advanced-metastatic-colorectal-cancer
#17
Dan-Zeng Ba-Sang, Zi-Wen Long, Hao Teng, Xu-Peng Zhao, Jian Qiu, Ming-Shan Li
OBJECTIVE: A network meta-analysis was conducted comparing the short-term efficacies of 16 targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer (CRC). RESULTS: Twenty-seven RCTs were ultimately incorporated into this network meta-analysis. Compared with chemotherapy alone, bevacizumab + chemotherapy, panitumumab + chemotherapy and conatumumab + chemotherapy had higher PR rate. Bevacizumab + chemotherapy, cetuximab + chemotherapy, panitumumab + chemotherapy, trebananib + chemotherapy and conatumumab + chemotherapy had higher ORR rate in comparison to chemotherapy alone...
October 31, 2016: Oncotarget
https://www.readbyqxmd.com/read/27805990/improving-mortality-in-trauma-laparotomy-through-the-evolution-of-damage-control-resuscitation-analysis-of-1-030-consecutive-trauma-laparotomies
#18
Bellal Joseph, Asad Azim, Bardiya Zangbar, Zachary M Bauman, Terence O'Keeffe, Kareem Ibraheem, Narong Kulvatunyou, Andrew Tang, Rifat Latifi, Peter Rhee
BACKGROUND: The aim of this study was to evaluate the related change in outcomes (mortality, complications) in patients undergoing trauma laparotomy (TL) with implementation of damage control resuscitation (DCR). We hypothesized that implementation of DCR in patients undergoing TL is associated with better outcomes. METHODS: We analyzed 1030 consecutive patients with TL. Patients were stratified into 3 phases: Pre-DCR (2006-2007), transient (2008-2009), and post-DCR (2010-2013)...
October 31, 2016: Journal of Trauma and Acute Care Surgery
https://www.readbyqxmd.com/read/27803866/outcomes-of-endoscopic-endonasal-dacryocystorhinostomy-for-intractable-lacrimal-dacryostenosis-and-associated-factors
#19
Tohru Tanigawa, Hirokazu Sasaki, Hiroshi Nonoyama, Yuichiro Horibe, Kunihiro Nishimura, Tetsuro Hoshino, Tetsuya Ogawa, Kenta Murotani, Hiromi Ueda, Masahiro Kaneda
AIM: To examine the effects of patient age, canalicular obstruction, mode of anesthesia, and duration of nasolacrimal intubation on the outcomes of endoscopic endonasal dacryocystorhinostomy (DCR). METHODS: Totally 56 eyes of 46 patients with prolonged epiphora underwent minimally invasive endoscopic endonasal DCR. A successful surgical outcome was defined as a significant improvement in symptoms, adequate water passage from the puncta to the nasal cavity, and patency of the DCR ostium...
2016: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/27793017/therapeutic-effect-of-apatinib-on-overall-survival-is-mediated-by-prolonged-progression-free-survival-in-advanced-gastric-cancer-patients
#20
Lihong Huang, Yongyue Wei, Sipeng Shen, Qianwen Shi, Jianling Bai, Jin Li, Shukui Qin, Hao Yu, Feng Chen
Apatinib is reported to significantly improve the overall survival (OS) of patients with advanced gastric cancer who have previously failed second-line chemotherapy. However, it is not well understood whether apatinib acts by improving progression or by prolonging post-progression survival. Here, based on phase III clinical trial data, the mediating effect of apatinib on patient overall survival was systematically quantified, through progression-free survival (PFS), post-progression survival (PPS), and the disease control rate (DCR)...
October 25, 2016: Oncotarget
keyword
keyword
15784
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"